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Abstract
The dopamine D2 receptor (DRD2) is a key receptor that mediates dopamine-associated brain functions such as mood,
reward, and emotion. Cyclin-dependent kinase 5 (Cdk5) is a proline-directed serine/threonine kinase whose function has
been implicated in the brain reward circuit. In this study, we revealed that the serine 321 residue (S321) in the third
intracellular loop of DRD2 (D2i3) is a novel regulatory site of Cdk5. Cdk5-dependent phosphorylation of S321 in the D2i3
was observed in in vitro and cell culture systems. We further observed that the phosphorylation of S321 impaired the
agonist-stimulated surface expression of DRD2 and decreased G protein coupling to DRD2. Moreover, the downstream
cAMP pathway was affected in the heterologous system and in primary neuronal cultures from p35 knockout embryos likely
due to the reduced inhibitory activity of DRD2. These results indicate that Cdk5-mediated phosphorylation of S321 inhibits
DRD2 function, providing a novel regulatory mechanism for dopamine signaling.
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Introduction
Dopamine signaling is involved in various brain functions
including motor coordination, mood control and reward mecha-
nisms [1]. A major component of dopamine signaling in
vertebrates is exerted by striatal medium spiny neurons (MSNs)
which selectively express a subset of dopamine receptors and
receive dopaminergic input mainly from the ventral tegmental
area (VTA) and substantia nigra (SN) [2]. Dopamine receptors are
G protein-coupled receptors (GPCR) with seven transmembrane
domains and consist of two subtypes, D1-like and D2-like
receptors, that mediate reciprocal actions in dopamine signaling
[1]. For example, dopamine D1-like receptors (D1, D5) activate
adenylyl cyclase through Gas and increase the intracellular level of
cAMP, but dopamine D2-like receptors (D2, D3, D4) inhibit
adenylyl cyclase through Gai and decrease the intracellular level of
cAMP [1,3].
Among dopamine receptors, the D2 receptor (DRD2) is
implicated in the pathophysiology of multiple major psychiatric
disorders including schizophrenia and drug addiction [4], such
that many antipsychotic drugs at least partially target DRD2. It is
also known that DRD2 activity correlates well with the behavioral
consequences of drugs of abuse in animal models [5]. Antidepres-
sants and mood stabilizer efficacy have also been linked to
alterations in the cell surface expression of DRD2 or downstream
intracellular signaling mediated by PKA, ERK and GSK3 [1,4,6].
Despite these critical roles for DRD2 in the brain, the detailed
regulatory mechanisms that confer heterogeneity and complexity
to DRD2 properties are not completely understood.
Converging lines of evidence indicate that multiple posttrans-
lational modifications are involved in the fine-tuning of DRD2
activity. Extensive glycosylation of DRD2 was revealed in early
photo-affinity labeling studies [7], and disulfide bond formation
within DRD2 was also identified as an important modification for
ligand binding [8]. Furthermore, phosphorylation sites of DRD2
were initially identified by in vitro assay with radioisotopes,
providing routes for various regulatory pathways mediated by
various kinases [9]. Indeed, protein kinase C (PKC) regulates
DRD2-mediated mobilization of intracellular calcium and mod-
ulates the interaction of DRD2 with cytoskeletal proteins [10].
Phosphorylation by GPCR kinase 2 (GRK2) regulates agonist-
induced resensitization patterns of DRD2 [11].
Cyclin-dependent kinase 5 (Cdk5) is a proline-directed serine/
threonine kinase that has preferential activity due to brain-specific
expression of its essential activators, p35 and p39 [12]. Cdk5 is
involved in various neuronal processes including neuronal
migration and axon guidance, and Cdk5 and p35 null mice show
defects in cortical layering [13]. Recently, it was shown that
phosphorylation of WAVE1 and ephexin by Cdk5 regulates
dendritic spine morphogenesis [14]. Furthermore, Cdk5 also
regulates surface expression levels of the NMDA receptor, NR2B,
and NR2A-mediated NMDA currents [15,16]. It is noteworthy
that multiple pieces of evidence suggest an intimate relationship
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between Cdk5 and the dopamine system. Cdk5 phosphorylates
tyrosine hydroxylase (TH), regulating its stability, and thus
maintaining dopaminergic homeostasis [17]. In postsynaptic
neurons, when the T75 residue of dopamine and cyclic-AMP
regulated phosphoprotein-32kD (DARPP-32) is phosphorylated by
Cdk5, it can inhibit PKA activity and thus antagonize dopamine
DRD1-mediated PKA signaling [18]. Interestingly, when cocaine,
an indirect agonist of dopamine receptors, is administrated
chronically in rats, mRNA and protein levels of Cdk5 increase
in medium spiny neurons [19]. Collectively, Cdk5 appears to be
involved in drug-induced synaptic adaptations. In this study, we
show a functional interaction of DRD2 and Cdk5 that further
extends the role of Cdk5 in dopamine signaling.
Materials and Methods
Antibodies
Anti-rabbit serums were raised against peptides containing
phospho-serine 321 (pS321) of the third intracellular loop of
DRD2 (D2i3). Phospho-peptide, CNPDpSPAKPEK (PEP-
TRON), was used to make a peptide-conjugated column for
affinity purification (20401, PIERCE). Anti-pS321 antibody was
enriched by an affinity purification system following the manu-
facturer’s instruction. Purified phospho-antibody was stored in
PBS with 0.1% sodium azide and 0.1% gelatin. Anti-mouse anti-
Cdk5 antibody (sc-249) and anti-rabbit anti-p35 antibody (sc-820)
were used for the Western blotting and immunocytochemistry of
Cdk5/p35. Anti-mouse anti-GFP antibody (sc-9996) was used for
the immunoprecipitation and Western blotting of DRD2-GFP.
Anti-rabbit anti-FLAG antibody (sc-807), anti-rabbit anti-HA
antibody (sc-805), anti-mouse anti-GST antibody (sc-138), and
anti-mouse anti-GAPDH antibody (sc-32293) were purchased
from Santa Cruz Biotechnologies.
Animals
The p35 knockout mouse was a kind gift from Dr. Katsuhiko
Mikoshiba at RIKEN Brain Science Institute in Japan and used
for primary neuron culture. Primer sets for genotyping were 59-
GGTCTCCTCTTCTGTCAAGAAG, 59-GCTCTGCTAGA-
CACATACTGTAC and 59- TCCATCT GCACGAGACTAGT
as previously described [20]. ICR mice and Sprague Dawley rats
were used for brain lysate preparation. All animal procedures were
approved by the Pohang University of Science and Technology
Institutional Animal Care and Use Committee.
Plasmid Constructs
Human DRD2 long isoform in an EGFP-N1 plasmid vector
and the third intracellular loop of DRD2 (212–373 amino acid
residues including the 29 additional amino acid residues unique to
DRD2 long isoform) in a pFLAG-CMV-2 plasmid vector were
used. Human Cdk5 was inserted in a pCMV-HA plasmid vector
and human p35 was inserted in a pcDNA 3.1 plasmid vector.
Human Cdk5 was inserted under a cytomegalovirus (CMV)
promoter along with human p35 in a pcDNA 3.1 vector to make a
dual expression construct (Cdk5/p35) for immunocytochemistry,
receptor internalization assay, [35S]-GTPcS binding assay, radio-
ligand binding assay and cAMP enzyme immunoassay.
In Vitro Kinase Assay
IP-linked in vitro kinase assay was performed as following. One
whole mouse brain was lysed in 3 mL erythrocytes lysis buffer
(ELB) (50 mM Tris (pH 8.0), 250 mM NaCl, 5 mM EDTA, 0.1%
NP-40) by 20 strokes of a Dounce homogenizer to get
homogenized brain lysates. The lysates were incubated on ice
for 30 min, sonicated, and centrifuged at 16,0006 g for 10 min.
The supernatants were immunoprecipitated with anti-rabbit anti-
p35 antibody to obtain an active Cdk5/p35 complex. Cdk5/p35
complex and purified GST fusion protein was mixed with
adenosine 59-triposphate, [c-32P] (NEG-502H, PerkinElmer) and
incubated in kinase buffer (30 mM HEPES (pH 7.2), 10 mM
MgCl2, 0.2 mM DTT) for 1 h at room temperature [18,21].
Purified Cdk5/p25 complex (14–516, Millipore) was also used for
in vitro kinase assay as described above. The 26 sample loading
buffer was added to the reaction mixture and boiled at 100uC. The
samples were then subjected to SDS-PAGE and the dried gel was
assessed by autoradiography.
Liquid Chromatography (LC)-Mass Spectrometry (MS)/MS
Analysis
The recombinant GST-D2i3 protein was analyzed by LC-MS/
MS following IP-linked in vitro kinase assay. We performed peptide
identification of LC-MS/MS data using X!!Tandem (version Dec-
01-2008). Each RAW data file was first converted to mzXML
using the trans-proteomic pipeline (TPP; version 4.3). MS/MS
scans in the converted mzXMLs were then subjected to search
against the UniProt mouse protein sequence database (release
2010_07) including GST-D2i3 sequence using X!!Tandem. The
tolerance was set to 3 Da for precursor ions and 2 Da for fragment
ions. Enzyme specificity for trypsin was used. Variable modifica-
tion options were used for the carbamidomethylation of cysteine
(57.021 Da), the oxidation of methionine (15.995 Da), the
hydrolysis of asparagine (0.987 Da) and the phosphorylation of
serine (79.966 Da).
Immunoprecipitation
Immunoprecipitation was performed on cell lysates in ELB lysis
buffer. Anti-GFP antibody was added to the lysates and incubated
for 3 h at 4uC. Immunocomplexes were purified using protein-A
agarose. The precipitates were incubated with SDS sample
loading buffer for 30 min at 37uC, and subjected to SDS-PAGE
and Western blots.
GST Pull-down Assay
10 mg of purified GST and GST–D2i3 were incubated with rat
brain lysate for 1.5 h at 4uC. 30 mL of glutathione (GSH)-
conjugated Sepharose 4B beads (17-0756-01, GE Healthcare)
equilibrated with lysis buffer was added and incubated for
additional 1 h. Beads were collected by centrifugation at
2,0006g and rinsed with lysis buffer 4 times [22,23]. Precipitates
were analyzed by Western blotting using anti-Cdk5 and anti-p35
antibodies.
Immunocytochemistry
Transfected HEK 293 cells and striatal neurons cultured on
coverslips were washed once with phosphate buffered saline (PBS)
and fixed by immersion in cold 4% paraformaldehyde/PBS for
30 min. Primary antibody was diluted in the blocking solution (2%
horse serum and 1% Triton X-100 in PBS). Alexafluor-647-
conjugated anti-mouse antibody (A20990, Invitrogen) and Alexa-
fluor-568-conjugated anti-rabbit antibody (A11011, Invitrogen)
were used as secondary antibodies. Hoechst were used for nucleus
staining. Images were obtained by confocal microscopy (Olympus,
FluoView-1000).
Receptor Internalization Assay
24 h after transfection, cells were treated with 1 mM quinpirole
(Q102, Sigma) for 30 min and 90 min at 37uC. Cells were re-
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suspended in 2 mL cold PBS and 200 mL aliquots were used for
each reaction. Drug treatments were carried out at room
temperature for 3 h at the following concentrations; 3 nM [3H]-
spiperone (NET-565, PerkinElmer), 3 mM sulpiride (895, TO-
CRIS), 10 mM haloperidol (H1512, Sigma). Hydrophobic [3H]-
spiperone was used to label total expressed receptors and
hydrophilic sulpiride was used to replace membranous receptor-
bound [3H]-spiperone signals. Membrane-associated receptor
signals were calculated by subtracting intracellular receptor values
from the total expressed receptor values. Cells were filtered on a
GF/B (Millipore) filter and washed 3 times with washing buffer
(50 mM Tris-HCl (pH 7.4), 100 mM NaCl). Filters were dried out
and residual radioactivity was measured using a liquid scintillation
counter [24].
Cell Membrane Preparation
Confluent cells in 100 mm culture-dishes after transfection were
washed with ice-cold PBS and harvested in 1 mL HME buffer
(25 mM HEPES (pH 7.5), 2 mM MgCl2, 1 mM EDTA).
Homogenized lysates were centrifuged with 5006g for 15 min
and the supernatants were subsequently centrifuged with
36,0006g for 30 min. Pellets re-suspended in HME buffer were
used for assays.
[35S]-GTPcS Binding Assay
Cell membrane fractions were pre-incubated with 1 mM
quinpirole (Q102, Sigma) in the assay buffer (25 mM HEPES
(pH 7.5), 1.5 mM MgCl2, 100 mM NaCl, 1 mM EDTA and
0.01 mM GDP) for 10 min. [35S]-GTPcS (NET-030H, PerkinEl-
mer) was added to the final concentration of 3 nM in 30 mL and
further incubated for 90 min. 170 mL of ice-cold buffer (10 mM
Tris-HCl (pH 8.0), 100 mM NaCl, 10 mM MgCl2, and 0.1 mM
GTP) was added to stop the reaction. Membranes were filtered on
a GF/B filter (Millipore) and washed 3 times with washing buffer
(50 mM Tris-HCl (pH 7.4), 100 mM NaCl). Filters were dried
and radioactivity was measured using the scintillation counter
[25,26].
Radioligand Binding Assay
Prepared cell membranes were incubated with 0.01 nM [3H]-
spiperone (NET-565, PerkinElmer) and increasing concentrations
of quinpirole (Q102, Sigma) for 30 min in the assay buffer (25 mM
HEPES (pH 7.5), 1.5 mM MgCl2, 100 mM NaCl, 1 mM EDTA).
Membranes were filtered on a GF/B filter (Millipore) and washed
3 times with washing buffer (50 mM Tris-HCl (pH 7.4), 100 mM
NaCl). The reaction was terminated by rapid filtration through
GF/C filters. Residual radioactivity was measured using a liquid
scintillation counter [27–29].
cAMP Enzyme Immunoassay
Transfected HEK 293 cells were pretreated with 10 mM
rolipram (R6520, Sigma) for 1 h, and then treated with 0.1 mM
forskolin (F6886, Sigma) and increasing concentrations of
quinpirole (Q102, Sigma) for 30 min. Primary cultured striatal
neurons were treated with 10 mM rolipram for 1 h, and then
1 mM dopamine for 1 h [22]. Cell lysates were prepared with 0.1
M HCl and cAMP levels were detected by cAMP enzyme
immunoassay kit (Sapphire Bioscience) following the manufactur-
er’s instruction.
Primary Cultured Striatal Neuron
Striatal area was isolated from the mouse embryonic brain
(E15). Dissected tissue was dissociated in minimal essential media
(MEM) (11095, Invitrogen) containing 0.25% trypsin (T4549-100,
Sigma) and 0.1% DNase I for 6 min at 37uC. Cells were re-
suspened in the plating media (MEM with 0.01 M HEPES
(pH 7.4) and 10% (vol/vol) horse serum (16050-122, GIBCO)).
Neurons were cultured for 7 days in vitro (DIV 7) in MEM with
B27 supplement (17504-044, Invitrogen) before being applied to
cAMP enzyme immunoassays.
Results
Cdk5 Phosphorylates Serine 321 in the Third Intracellular
Loop of DRD2 in vitro
To identify novel Cdk5 substrates, we performed a systematic
search using (S/T)PX(K/H/R) as the Cdk5 recognition consensus
sequences [30] and identified DRD2 as a candidate substrate. The
consensus sequence, including serine 321, is located in the third
intracellular loop of DRD2 (D2i3) where various regulatory
mechanisms have been implicated [3,10,11]. The sequence is
evolutionarily conserved in DRD2 in vertebrates, implying a
functional importance of the residue (Fig. 1A).
To assess the capacity of Cdk5 to phosphorylate D2i3, we
performed IP-linked in vitro kinase assays using an active Cdk5/
p35 complex enriched from mouse brain lysate by p35 immuno-
precipitation with purified recombinant GST-D2i3 (amino acid
residues 212–373) proteins as the substrates. We observed
phosphorylation signals in the purified GST-D2i3 and GST-
D2i3 S297A proteins, but the signal was significantly diminished
using GST-D2i3 S321A (Fig. 1B). To further verify phosphory-
lation of serine 321 in the GST-D2i3, we performed LC-MS/MS
analysis of the samples from IP-linked in vitro kinase assays using
LTQ XL mass spectrometry. Consistently, phospho-peptides
corresponding to the mass of phospho-serine 321 peptides were
recovered (Fig. 1C). Considering that the data-dependent acqui-
sition during LC-MS/MS analysis tends to detect abundant
proteins in the sample [31], this data suggests that the serine 321
residue is the dominant phosphorylation site of Cdk5 in the D2i3
region. To prove direct phosphorylation of serine 321 in the GST-
D2i3 by Cdk5, in vitro kinase assay using purified Cdk5/GST-p25
complex with purified recombinant GST-D2i3 proteins was
performed. We identified a significant phosphorylation signal in
the GST-D2i3 that was absent in the GST-D2i3 S321A (Fig. 1D).
Taken together, these results indicate that the D2i3 S321 residue is
a preferential target for Cdk5-mediated phosphorylation.
Cdk5 Phosphorylates Serine 321 in the Third Intracellular
Loop of DRD2 in Cells
To identify the phosphorylation of serine 321, we raised
antibody specific for phospho-serine 321 (pS321). Samples from
the IP-linked in vitro kinase assay were analyzed by Western
blotting using anti-pS321 antibody. Blots showed a distinct band
in the kinase reaction that was dependent on GST-D2i3 (Fig. 2A).
To verify the potential phosphorylation of serine 321 in DRD2 by
Cdk5 in cells, anti-GFP immunoprecipitates from HEK 293 cells
expressing DRD2-GFP and DRD2 S321A-GFP with or without
HA-Cdk5 and p35 were analyzed by Western blotting using anti-
GFP and anti-pS321 antibodies. Characteristic smeared band
signals by anti-GFP antibody that are known to be due to excessive
glycosylation of DRD2 are observed only in the presence of
DRD2-GFP, and anti-pS321 antibody detected similar DRD2
signals only with Cdk5/p35 co expression (Fig. 2B) [7]. To further
verify the phosphorylation of serine 321 by Cdk5, D2i3 (FLAG-
D2i3) and mutant form of D2i3 (FLAG-D2i3 S321A) were
generated. FLAG-D2i3 and FLAG-D2i3 S321A expressed with or
without HA-Cdk5 and p35 in HEK 293 cells were analyzed by an
DRD2 as a Novel Substrate of Cdk5
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SDS-gel mobility shift assay. A significant Cdk5-dependent
mobility shift was observed for FLAG-D2i3, but not for FLAG-
D2i3 S321A (Fig. 2C). We also assessed the phosphorylation level
of DRD2 at Ser321 upon agonist stimulation. HEK 293 cells
expressing DRD2-GFP and Cdk5/p35 complex were stimulated
by quinpirole, and anti-GFP immunoprecipitates from the cell
lysates were analyzed by Western blotting using anti-GFP and
anti-pS321 antibodies. We found that Cdk5-mediated phosphor-
ylation of DRD2 at Ser321 was not affected by agonist
stimulation, which appears different from GRK- and PKC-
mediated phosphorylations (Fig. 2D) [32,33]. Together, these
results indicate that Cdk5 can phosphorylate the serine 321
residue of DRD2 in the cellular environment.
Cdk5/p35 Complex and DRD2 are Physically Associated
We investigated the potential physical interaction between the
Cdk5/p35 complex and DRD2 because many Cdk5 substrates are
known to be physically associated with Cdk5/p35 complex
[23,34,35]. First, the GST pull-down experiment was performed.
Purified recombinant GST-D2i3 protein was incubated with rat
brain lysate and GST pull-down precipitates were analyzed for
Western blotting. As shown in Fig. 3A, endogenous Cdk5 and p35
were identified in the pull-down precipitates, indicating a physical
interaction between DRD2 and the Cdk5/p35 complex (Fig. 3A).
Moreover, HA-Cdk5 and p35 were detected in the anti-GFP
immunoprecipitates from HEK 293 cell lysates expressing DRD2-
GFP and Cdk5/p35 (Fig. 3B). In addition, we performed immuno-
cytochemicalanalysesandobservedthatDRD2-GFP,HA-Cdk5and
p35 show significant co-localization signals at the membranous area
of HEK 293 cells (Fig. 3C, upper panels). We also investigated co-
localization of DRD2 and Cdk5/p35 in the neuronal context.
Consistently, DRD2-GFP also showed significant co-localization
with endogenous Cdk5 and p35 in the cultured striatal neurons
(DIV7), further supporting functional links between DRD2 and
Cdk5/p35 (Fig. 3C, bottom panels). The results indicate that DRD2
andCdk5/p35 can forma complex and thus, support the notion that
DRD2 is a physiological substrate of Cdk5.
Cdk5-mediated Phosphorylation of DRD2 Attenuates
Receptor Activity
It has been reported that phosphorylation modulates critical
properties of GPCRs such as G protein coupling, receptor
Figure 1. Cdk5 phosphorylates serine 321 in the third intracellular loop of DRD2 in vitro. (A) Amino acid sequence alignment showing
conserved regions of the DRD2 from various species (shaded). The potential Cdk5 phosphorylation site is indicated by an asterisk. (B) IP-linked in vitro
kinase assay with recombinant GST-D2i3 and GST-D2i3 mutant proteins. Cdk5/p35 complex enriched from mouse brain extract by anti-p35
immunoprecipitation was used for kinase reactions. An autoradiograph of phosphorylated proteins is shown along with Coomassie brilliant blue
staining of the same gel. Arrowhead indicates radioactive signal corresponding to GST-D2i3s and open arrowhead indicates radioactive signals from
p35. (C) MS/MS spectrum of the phosphorylated peptide fragment of D2i3. The theoretical fragmentation patterns are shown below the spectrum.
Among all the fragment ions, the detected y- and b-ions are denoted in the spectrum. The y6 and y7 ions strongly indicate the phosphorylation of
serine 321. (D) In vitro kinase assay with purified Cdk5/GST-p25 complex using GST-D2i3 and GST-D2i3 mutant proteins. Phosphorylated proteins
were shown in an autoradiograph, along with Coomassie brilliant blue staining. Arrowhead indicates radioactive signal corresponding GST-D2i3 and
open arrowhead indicates radioactive signals from GST-p25.
doi:10.1371/journal.pone.0084482.g001
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internalization, intracellular localization, and association with
modulator proteins [9,11,24]. Agonist-induced receptor internal-
ization is a critical regulatory process of signal transduction. We
investigated Cdk5-mediated modulation of DRD2 internalization.
HEK 293 cells expressing DRD2-GFP and DRD2 S321A-GFP
with or without Cdk5/p35 were incubated with 1 mM quinpirole
to induce agonist-stimulated DRD2 internalization (Fig. 4A). [3H]-
spiperone signals of DRD2-GFP expressing cells were significantly
reduced at 30 min quinpirole treatment and recovered at 90 min.
Interestingly, [3H]-spiperone signals of DRD2-GFP and Cdk5/
p35 expressing cells were also reduced at 30 min quinpirole
treatment but not recovered at 90 min (Fig. 4A, second section).
On the other hand, [3H]-spiperone signals of DRD2 S321A-GFP
expressing cells were reduced at 30 min and recovered at 90 min,
regardless of the co-expression with Cdk5/p35. Previous studies
have shown that the internalized DRD2 recycles back to the
plasma membrane upon prolonged agonist stimulation [11]. Thus
it appears that Cdk5-mediated phosphorylation of DRD2 is
involved in the resensitization processes following agonist-induced
DRD2 internalization.
We further evaluated a potential change of agonist-stimulated G
protein coupling to DRD2 associated with Cdk5-mediated
phosphorylation using [35S]-GTPcS binding assay [25,26].
DRD2-GFP and DRD2 S321A-GFP with or without Cdk5/p35
were expressed in HEK 293 cells. Membranes were prepared and
stimulated with 1 mM quinpirole and further allowed [35S]-GTPcS
Figure 2. Cdk5 phosphorylates serine 321 in the third intracellular loop of DRD2 in cells. Cdk5-mediated phosphorylation of serine 321
was analyzed using anti-pS321 antibody. (A) Samples from IP-linked in vitro kinase assay using GST-D2i3 proteins were analyzed by Western blotting
(WB) with indicated antibodies. Arrowheads indicate GST-D2i3s. (B) DRD2-GFP and DRD2 S321A-GFP was expressed with or without HA-Cdk5 and p35
in HEK 293 cells. Anti-GFP immunoprecipitates were analyzed by Western blotting using anti-GFP and anti-pS321 antibodies. The bracket indicates
DRD2 signals and open arrowhead indicates nonspecific signals from the anti-GFP immunoprecipitates. ‘% input’ is % volume of total lysate for an IP
reaction. Weak endogenous Cdk5 signals were indicated by asterisks. (C) Gel mobility shift assay. HEK 293 cells transfected as indicated were analyzed
by Western blotting. (D) Transfected HEK 293 cells were treated with quinpirole and anti-GFP immunoprecipitates were analyzed by Western blotting
with anti-GFP and anti-pS321 antibodies. Open arrowhead indicates nonspecific signals from anti-GFP immunoprecipitates.
doi:10.1371/journal.pone.0084482.g002
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incorporation. DRD2-GFP and Cdk5/p35 expressing cell mem-
brane showed significantly impaired [35S]-GTPcS binding com-
pared to all the other cell membranes (Fig. 4B). These results
indicate that Cdk5-mediated phosphorylation down-regulates
agonist-stimulated G protein binding at DRD2.
Additionally, quinpirole-competing [3H]-spiperone binding
assays were performed to investigate any potential change in
agonist-affinity at DRD2 by Cdk5-mediated phosphorylation.
Competitive binding of [3H]-spiperone upon treatment of
increasing concentrations of quinpirole to the membrane prepa-
ration from transfected was measured. Competing binding of
quinpirole and [3H]-spiperone at DRD2-GFP and DRD2 S321A-
GFP made similar logKi values (29.789 for DRD2-GFP; 29.691
for DRD2 S321A-GFP), indicating that the affinity of ligand to
DRD2 is not significantly affected by Cdk5-mediated phosphor-
ylation at DRD2 (Fig. 4C).
Figure 3. Cdk5/p35 can form a complex with DRD2. (A) GST pull-down assay using purified recombinant GST-D2i3 protein with rat brain
extract. GST pull-down precipitates were subjected to Western blotting analyses. ‘Bead’ indicates the pull-down precipitate without GST proteins. (B)
Immunoprecipitation of DRD2 and Cdk5/p35 complex. Anti-GFP IP from lysates from transfected cells were subjected to Western blotting analyses.
The bracket indicates DRD2 signals and open arrowhead indicates nonspecific signals from the anti-GFP immunoprecipitates. An overexposed blot
for inputs is also shown in the right. (C) Immunocytochemical analyses of DRD2 and Cdk5/p35. HEK 293 cells expressing DRD2-GFP and Cdk5/p35
were stained with anti-Cdk5 and anti-p35 antibodies (Upper panels). DRD2-GFP was expressed alone in the cultured striatal neurons and stained with
anti-Cdk5 and anti-p35 antibodies (Lower panels). Hoechst were used for nucleus staining. The scale bar is 5 mm. All images were obtained using
confocal microscopy (Olympus, FluoView-1000).
doi:10.1371/journal.pone.0084482.g003
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Cdk5-mediated Phosphorylation Down-regulates the
DRD2-cAMP Signaling Pathway
Next, we investigated whether the modification of DRD2 by
Cdk5 affects downstream signaling pathways. We monitored
DRD2-mediated inhibition of forskolin-stimulated cAMP produc-
tion by adenylyl cyclase in the cells expressing DRD2-GFP and
DRD2 S321A-GFP using cAMP enzyme immunoassay. DRD2-
expressing cells showed decreased cAMP levels in response to
quinpirole in a dose-dependent manner. Remarkably, co-expres-
sion of Cdk5/p35 significantly reduced the maximal inhibition of
cAMP formation (Fig. 4D, left panel). On the other hand, in the
DRD2 S321A-GFP expressing cells, the cAMP formations were
Figure 4. Cdk5-mediated phosphorylation attenuates DRD2 surface expression and downstream signaling. (A) DRD2 surface
expression measured by [3H]-spiperone binding assay. Transfected HEK293 cells were stimulated with 1 mM quinpirole for the indicated time and
harvested, followed by 3 nM [3H]-spiperone treatment for 3 h. Radioactivity was measured and surface signals were calculated. Error bars represent
mean 6 SE (n = 8; *p,0.05, **p,0.01; One-way ANOVA with Dunnett post hoc test: compare all columns vs. control column). (B) [35S]-GTPcS binding
assay. Cell membranes were prepared from the cells transfected as indicated. Membrane preparations were incubated with 1 mM quinpirole followed
by 3 nM [35S]-GTPcS for 90 min. Error bars represent mean 6 SE (n = 8; *p,0.05, **p,0.01, ***p,0.001; One-way ANOVA with Bonferroni post hoc
test: compare all pairs of columns). (C) Quinpirole-competing [3H]-spiperone binding assay. Membrane preparations from transfected cells were
incubated with 0.01 nM [3H]-spiperone and increasing concentrations of quinpirole for 30 min. Non-linear regression was obtained by GraphPad.
Error bars indicate mean 6 SE (n = 3). (D) cAMP enzyme immunoassays in transfected HEK 293 cells. Transfected cells were pretreated with 10 mM
rolipram for 1 h, and subsequently co-treated with 0.1 mM forskolin and increasing concentrations of quinpirole for 30 min. Non-linear regression was
obtained by GraphPad. Error bars represent mean 6 SE (n = 4; **p,0.01; two-tailed t-tests). (E) Cultured striatal neurons from wild type and p35
knockout embryos (DIV 7) were treated with 10 mM rolipram for 1 h followed by 1 mM dopamine for 1 h. Error bars represent mean 6 SE (n = 4;
**p,0.01; two-tailed t-tests).
doi:10.1371/journal.pone.0084482.g004
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effectively inhibited in response to quinpirole treatment regardless
of the expression of Cdk5/p35 (Fig. 4D, right panel). These results
indicate that Cdk5-mediated phosphorylation of DRD2 attenuates
the inhibitory activity of DRD2 on the downstream cAMP
signaling pathway. To further confirm the phenomena in a more
physiologically relevant setting, we made use of primary cultured
neurons from knockout embryos deficient in p35, an essential
Cdk5 activator. Primary cultured striatal neurons were treated
with 1 mM dopamine and analyzed by cAMP enzyme immuno-
assay. Neurons from p35 knockout mice exhibited reduced cAMP
levels compared to wild-type neurons when stimulated with
dopamine (Fig. 4E). Taken together, we concluded that Cdk5-
mediated phosphorylation of DRD2 results in a decrease in the
inhibitory tone on the cAMP pathway exerted by DRD2.
Discussion
We identified DRD2 as a novel substrate of Cdk5. The
phosphorylation appears to down-regulates DRD2 surface expres-
sion by affecting the fate of DRD2 following receptor internali-
zation thereby reducing DRD2 Gi-coupling and downstream
cAMP pathway. As the phosphorylation residue S321 exists both
in DRD2 long and short isoforms, the mechanism proposed in this
study may be a general mode of regulation in DRD2-mediated
signaling.
DRD2 in medium spiny neurons has not only been regarded as
a major dopamine receptor subtype but has also been recognized
for its susceptibility to changes in availability in response to
environmental stimuli. Agonist-induced desensitization and re-
sensitization of DRD2 have been extensively studied [11,24]. In
particular, a number of studies have shown that the effects of
chronic psychostimulant exposure, such as cocaine and amphet-
amine, which raise the extracellular level of dopamine in the
striatal synapse, are accompanied by dynamic changes of DRD2
postsynaptically [36]. Indeed, chronic cocaine users are known to
have reduced DRD2 levels in the striatal area, and DRD2
availability in the nucleus accumbens (NAcc) shows a negative
correlation with the drug seeking and reinforcement behaviors in
mice and primates [37–39]. These findings indicate that the
functionality of DRD2 is highly susceptible to adaptive or
compensatory regulation in response to various stimuli including
chronic drug exposure. Our results show that the S321 residue in
the third intracellular loop of DRD2 can be phosphorylated by
Cdk5, which results in a decrease in inhibitory influence of DRD2
on the cAMP pathway. This interaction proposes a novel
regulatory mechanism associated with Cdk5 in dopaminoceptive
neurons that might be linked to the dynamic nature of DRD2
surface availability.
It should be noted that Cdk5 is known to be a key component in
mediating adaptive changes of the neuronal environment. For
instance, structural and functional alterations of dendritic spines in
the neurons of the limbic circuit are one of the consequences of
repeated psychostimulant exposure [40]. These changes are
accompanied by various molecular changes including the induc-
tion of cAMP response element-binding protein (CREB) and
DFosB, transcription factors that exhibit an enduring up-regula-
tion in response to chronic cocaine administration [41,42].
Importantly, Cdk5 is a target of DFosB [19], and many critical
components involved in dendritic spine dynamics, such as PSD-95,
p21-activated kinase (PAK), b-catenin, and spinophilin, were
reported as Cdk5 substrates [43–46]. Consistently, genetic or
pharmacological manipulations of Cdk5 activity elicit alterations
of dendritic spine morphology and behavioral responses to
cocaine, implying critical roles for Cdk5 in the molecular and
morphological changes of mesolimbic dopamine circuits [47,48].
Our results showing that DRD2 is a novel target of Cdk5 provides
additional insight into the adaptive changes of the dopamine
system in response to chronic drug exposures because of the
subsequent DFosB-mediated up-regulation of Cdk5 may induce a
tonic increase in the phosphorylation of DRD2. Moreover, DRD2
is known to affect numerous cellular processes, including
regulation of cAMP and MAP kinase pathways and downstream
transcriptional events [42,49]. Thus, the findings in this study
might not only depict a direct regulation of DRD2 by Cdk5 but
also provide a novel insight into the adaptive responses of
dopamine system to chronic drug exposure.
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